Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Diacerein (Primary)
- Indications Fatty liver; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DGCLFT2DM
- 07 Jun 2017 Biomarkers information updated
- 05 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 05 May 2017 Status changed from recruiting to active, no longer recruiting.